Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
RANCHO CORDOVA, Calif., March 30, 2011 /PRNewswire/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that Nanshan Memorial Medical Institute (Nanshan), a leading regenerative medicine company, will be utilizing its AXP® AutoXpress™ (AXP) and BioArchive® Systems used to process and store stem cells from cord blood in its two stem cell banks in China. The Nanshan facilities are located in Biolake, Wuhan City, a Hubei provincial government supported hi-tech zone specializing in biotechnology and in Jiuzhou Biotechnology Research Park in Xian City, Shanxi Province. Nanshan expects to procure over time the necessary processing and cryopreservation storage capacity to process and store up to several hundred thousand stem cell units at each facility.
Nanshan is a progressive regenerative medicine company that distributes medical products and has operated multiple, large healthcare facilities, including hospitals, stem cell banks and research centers.
Nanshan's decision to adopt ThermoGenesis' cord blood technologies follows a four-year distribution agreement between ThermoGenesis and Nanshan signed late last year under which Nanshan will distribute in China and Hong Kong ThermoGenesis' Res-Q™ 60 BMC (Res-Q) System and MXP™ MarrowXpress™ products used to prepare cell concentrates—including stem cells—from bone marrow at the point-of-care and in the laboratory.
"We are delighted to be expanding our relationship with Nanshan as we continue to implement a key element of our growth strategy by broadening the geographic reach of our offerings into potential high growth markets," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.
"Dr. Lu Daopei, founder and medical director of Nanshan,